

16. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang J, et al. (2010) Natural history of retinal vein occlusion: An evidence-based systematic review. *Ophthalmology* 117: 1113-1123.
17. Jin KL, Mao XO, Greenberg DA (2000) Vascular endothelial growth factor: Direct neuro protective effect in in vitro ischemia. *PNAS* 97: 10242-10247.
18. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, et al. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 331: 1480-1487.
19. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, et al. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a non-human primate. *Arch Ophthalmol* 114: 66-71.
20. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E (1998) Vascular endothelial growth factor upregulation in human central retinal vein occlusion. *Ophthalmology* 105: 412-416.
21. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, et al. (2002) Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. *Arch Ophthalmol* 120: 1644-1650.
22. Kaur C, Foulds WS, Ling EA. (2008) Blood-retinal barrier in hypoxic ischemic conditions: Basic concepts, clinical features and management. *Prog Retin Eye Res* 27: 622-647.
23. Noma H, Funatsu H, Mimura T, Harino S, Hori S (2009) Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. *Ophthalmology* 116: 87-93.
24. Noma H, Funatsu H, Harino S, Mimura T, Eguchi S, Hori S (2011) Vitreous inflammatory factors in macular edema with central retinal vein occlusion. *Jpn J Ophthalmol* 55: 248-255.
25. Jung SH, Kim KA, Sohn SW, Yang SJ (2014) Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. *Invest Ophthalmol Vis Sci* 55: 2290-2296.
26. Shchuko AG, Zlobin IV, Iureva TN, Ostanin AA, Chernykh ER, Mikhalevich IM (2015) Intraocular cytokines in retinal vein occlusion and its relation to the efficiency of anti-vascular endothelial growth factor therapy. *Indian J Ophthalmol* 63: 905-911.
27. Rezar-Dreindl S, Eibenberger K, Pollreis A, Bühl W, Georgopoulos M, et al. (2017) Effect of intravitreal dexamethasone implant on intra-ocular cytokines and chemokines in eyes with retinal vein occlusion. *Acta Ophthalmol* 95: e119-e127.
28. The central vein occlusion study group N report (1995) A randomized clinical trial of early pan retinal photocoagulation for ischemic central vein occlusion. *Ophthalmology* 102: 1434-1444.
29. The central vein occlusion study group M report (1995) Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. *Ophthalmology* 102: 1425-1433.
30. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, et al. (2010) Ranibizumab for macular edema following central retinal vein occlusion. *Ophthalmology* 117: 1124-1133.
31. Campochiaro PA, Brown DM, Awh CC, Lee Y, Gray S, et al. (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: Twelve month outcomes of a phase III study. *Ophthalmology* 118: 2041-2049.
32. Brown DM, Heier JS, Clark L, Boyer DS, Vitti R, et al. (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1 year results from the phase 3 COPERNICUS study. *Am J Ophthalmol* 155: 429-437.
33. Korobelnik J-F, Holz FG, Roeder J, Ogura Y, Simader C, et al. (2014) Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: 1 year results of the phase 3 GALILEO study. *Ophthalmology* 121: 202-208.
34. Ford JA, Clar C, Lois N, Barton S, Thomas S, et al. (2014) Treatments for macular edema following central retinal vein occlusion: Systematic review. *BMJ Open* 4: e004120.
35. Yeh S, Kim SJ, Ho AC, Schoenberger S, Bakri S, et al. (2015) Therapies for macular edema associated with central retinal vein occlusion. *Ophthalmology* 122: 769-778.
36. Ho M, Liu DTL, Lam DSC, Jonas JB (2016) Retinal vein occlusions, from basics to the latest treatment. *Retina* 36: 432-448.
37. Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, et al. (2012) Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. *Ophthalmology* 119: 802-809.
38. Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, et al. (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. *Ophthalmology* 121: 1414-1420.
39. Ogura Y, Roeder J, Korobelnik J-F, Holz FG, Simader C, et al. (2014) Intravitreal aflibercept for macular

- edema secondary to central retinal vein occlusion: 18 month results of the phase 3 GALILEO study. *Am J Ophthalmol* 158: 1032-1038.
40. Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, et al. (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The standard care vs. corticosteroid for retinal vein occlusion (SCORE) study report 5. *Arch Ophthalmol* 127: 1101-1114.
 41. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Sophie R, et al. (2015) Pro-permeability factors after dexamethasone implant in retinal vein occlusion; the ozurdex for retinal vein occlusion (ORVO) study. *Am J Ophthalmol* 160: 313-321.
 42. Haller JA, Bandello F, Belfort R Jr, Blumenkrantz MS, Gillies M, et al. (2010) Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 117: 1134-1146.
 43. Chiquet C, Dupuy C, Bron AM, Aptel F, Straub M, et al. (2015) Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: A 12 month follow-up study. *Graefes Arch Clin Exp Ophthalmol* 253: 2095-2102.
 44. Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, et al. (2014) Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). *Retina* 34: 342-351.
 45. Reid GA, Sahota DS, Sarhan M (2015) Observed complications from dexamethasone intravitreal implant for the treatment of macular edema in retinal vein occlusion over 3 treatment rounds. *Retina* 35: 1647-1655.
 46. Caillaux V, Valtot F, Souied EH, Mimoun G (2015) Intraocular pressure after intravitreal injection of dexamethasone implant for macular edema resulting from retinal vein occlusion. *Eur J Ophthalmol* 25: 454-458.
 47. Garweg JG, Zandi S. (2016) Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. *Graefes Arch Clin Exp Ophthalmol* 254: 1257-1265.
 48. Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG (2013) Vascular endothelial growth factor promotes progressive retinal non-perfusion in patients with retinal vein occlusion. *Ophthalmology* 120: 795-802.
 49. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, et al. (2013) Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal non-perfusion. *Am J Ophthalmol* 156: 693-705.
 50. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, et al. (2015) Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion. *Ophthalmology* 122: 1426-1437.
 51. Mir TA, Kherani S, Hafiz G, Scott AW, Zimmer-Galler I, et al. (2016) Changes in retinal non-perfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion. *Ophthalmology* 123: 625-634.
 52. Chan CK, Ip MS, van Veldhuisen PC, Oden NL, Scott I, et al. (2011) SCORE study report 11: Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 118: 1364-1372.
 53. Sadda S, Danis RP, Pappuru RR, Keane PA, Jiao J, et al. (2013). Vascular changes in eyes treated with dexamethasone intravitreal implant for macular edema after retinal vein occlusion. *Ophthalmology* 120: 1423-1431.
 54. Singer M, Tan CS, Bell D, Sadda SR (2014) Area of peripheral retinal non-perfusion and treatment response in branch and central retinal vein occlusion. *Retina* 34: 1736-1742.
 55. Wykoff CC, Brown DM, Croft DE, Major JC Jr, Wong TP (2015) Progressive retinal non-perfusion in ischemic central retinal vein occlusion. *Retina* 35: 43-47.
 56. Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE Schuetzle KL (2014) Ranibizumab in pre-proliferative (ischemic) central retinal vein occlusion: The rubeosis anti-VEGF (RAVE) trial. *Retina* 34: 1728-1735.
 57. Ryu CL, Elfersy A, Desai U, Hessburg T, Edwards P, Gao H (2014) The effect of anti-vascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: A retrospective analysis. *J Ophthalmol* 2014: 317694.
 58. DeCroos FC, Todorich B, Alshareef R, Khuthaila M, Fekrat S, et al. (2014) Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: A retrospective review. *J Ophthalmic Vis Res* 9: 461-468.
 59. Gardašević Topčić I, Šuštar M, Breclj J, Hawlina M, Mekjavić P (2014) Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to

- central retinal vein occlusion. *Doc Ophthalmol* 129: 27-38.
60. Wittström E, Holmberg H, Hvarfner C, Andréasson S (2012) Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. *Eur J Ophthalmol* 22: 563-574.
 61. McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, et al. (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). *Doc Ophthalmol* 130: 1-12.
 62. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, et al. (2013) Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. *Eye* 27: 816-822.
 63. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, et al. (2014) Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN study. *Ophthalmology* 121: 209-219.
 64. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A (2013) Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. *Eye* 27: 65-71.
 65. Lüke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, et al. (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. *Br J Ophthalmol* 90: 1178-1182.
 66. Stahl A, Feltgen N, Fuchs A, Bach M (2009) Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. *Doc Ophthalmol* 118: 81-88.
 67. Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, et al. (2008) Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, color vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. *Int Ophthalmol* 28: 101-109.
 68. Januschowski K, Schnichels S, Hagemann U, Koch V, Hofmann J, et al. (2014) Electrophysiological toxicity testing of VEGF Trap-Eye in an isolated perfused vertebrate retina organ culture model. *Acta Ophthalmol* 92: e305-e311.
 69. Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, et al. (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. *Doc Ophthalmol* 116: 129-135.
 70. Bjerg Pedersen K, Møller F, Sjølie AK, Andréasson S (2010) Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. *Retina* 30: 1025-1033.
 71. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, et al. (2007) Ultra structural findings in the primate eye after intravitreal injection of bevacizumab. *Am J Ophthalmol* 143: 995-1002.
 72. Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, et al. (2005) Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. *Am J Pathol* 167: 1451-1459.
 73. Nishijima K, Ng Y-S, Zhong L, Bradley J, Schubert W, et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuro protectant during the adaptive response to ischemic injury. *Am J Pathol* 171: 53-67.
 74. Avci B, Avci R, Inan ÜÜ, Kaderli B (2009) Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. *Invest Ophthalmol Vis Sci* 50: 3438-3446.
 75. Saint-Geniez M, Maharaj ASR, Walshe T, Tucker BA, Sekiyama E, et al. (2008) Endogenous VEGF is required for visual function: Evidence for a survival role on Müller cells and photoreceptors. *PLoS* 3: e3554.